AQST
BEARISH
$4.02
Live
Aquestive Therapeutics, Inc. · NASDAQ
Target $8.89
(+121.1%)
$2.12
52W Range
$7.55
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$490.45M
P/E
N/A
ROE
N/A
Profit margin
-188.1%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AQST exhibits severe financial distress despite modest revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports massive negative profitability metrics, including a -188.09% profit margin and -33.92% ROA, with no meaningful earnings or cash flow generation. Insider selling totaling $1.86M over six months, including significant sales by top executives, signals deep skepticism about future prospects. While the stock trades below its 52-week high and has a strong analyst consensus, the lack of intrinsic value support and deteriorating earnings trends undermine long-term viability. The absence of a valid Altman Z-Score and Graham Number further limits fundamental valuation reliability.
Key Strengths
Gross margin of 58.34% suggests strong pricing power or cost control in product manufacturing
Revenue growth of 9.70% YoY indicates some market traction despite losses
Current ratio of 3.13 and quick ratio of 2.92 reflect strong short-term liquidity
Analyst consensus is strong_buy, indicating potential upside expectations
Historical EPS surprises have occasionally been positive, showing occasional outperformance
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative ROA (-33.92%) and ROE (N/A) indicate capital is not being deployed effectively
Insider selling by CEO, CFO, and COO totaling $1.86M in six months is a major red flag
No positive free cash flow or operating cash flow data; business not generating cash
Forward P/E of -6.93 and negative earnings imply continued losses, raising sustainability concerns
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
20
45
38
15
0
AI Verdict
Weak
Key drivers: Piotroski F-Score of 1/9, Negative profitability and cash flow, Insider selling activity, Lack of intrinsic value metrics, High valuation multiples despite losses
Confidence
88%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 11.01 is below sector average of 164.56, suggesting relative valuation appeal
Watchpoints
- No Graham Number or intrinsic value estimate available
- Negative P/E and PEG ratios make traditional valuation impossible
- Price/Sales is high relative to earnings sustainability
- Stock trades at a premium despite negative earnings and cash flow
Future
45/100
Ref Growth rates
Positives
- 9.70% YoY revenue growth indicates market expansion
- Some recent quarters have shown positive EPS surprises
Watchpoints
- Forward P/E of -6.93 implies continued losses
- No positive free cash flow or operating cash flow data
- Earnings growth is not sustainable given current loss levels
- Q/Q EPS growth of -27.3% shows worsening profitability
Past
38/100
Ref Historical trends
Positives
- Historical EPS surprises have occasionally been large and positive (e.g., +275.5%)
- Some quarters show improvement in earnings relative to estimates
Watchpoints
- Consistently negative earnings over 25 quarters
- Most recent quarter missed estimates by 18.1%
- Negative trend in earnings progression over the last 4 quarters
- High volatility in earnings surprises without sustained improvement
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and quick ratios above 2.9, indicating strong liquidity
Watchpoints
- Piotroski F-Score of 1/9 is extremely low, indicating poor financial health
- No Altman Z-Score available, but negative ROA and profitability suggest distress risk
- Negative ROA (-33.92%) and gross margin not offsetting massive losses
- No debt/equity or cash/debt data, but high loss levels imply funding pressure
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is not generating profits, making dividends impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.02
Analyst Target
$8.89
Upside/Downside
+121.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AQST and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
Primary
|
-27.7% | +432.4% | +47.8% | -20.4% | +5.2% | -4.7% |
|
BWAY
BrainsWay Ltd.
Peer
|
+163.4% | +1289.2% | +184.8% | +61.0% | -3.2% | -7.8% |
|
KMDA
Kamada Ltd.
Peer
|
+49.5% | +95.6% | +48.0% | +28.6% | +2.3% | +0.2% |
|
RGNX
REGENXBIO Inc.
Peer
|
-72.0% | -49.8% | +59.8% | -19.1% | +14.6% | +7.8% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-49.3% | +20.9% | +23.6% | +7.9% | +5.1% | +6.4% |
AQS
Aquestive Therapeutics, Inc.
Primary
5Y
-27.7%
3Y
+432.4%
1Y
+47.8%
6M
-20.4%
1M
+5.2%
1W
-4.7%
BWA
BrainsWay Ltd.
Peer
5Y
+163.4%
3Y
+1289.2%
1Y
+184.8%
6M
+61.0%
1M
-3.2%
1W
-7.8%
KMD
Kamada Ltd.
Peer
5Y
+49.5%
3Y
+95.6%
1Y
+48.0%
6M
+28.6%
1M
+2.3%
1W
+0.2%
RGN
REGENXBIO Inc.
Peer
5Y
-72.0%
3Y
-49.8%
1Y
+59.8%
6M
-19.1%
1M
+14.6%
1W
+7.8%
ANG
AngioDynamics, Inc.
Peer
5Y
-49.3%
3Y
+20.9%
1Y
+23.6%
6M
+7.9%
1M
+5.1%
1W
+6.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-6.93
PEG Ratio
N/A
P/B Ratio
-14.57
P/S Ratio
11.01
EV/Revenue
9.25
EV/EBITDA
-5.84
Market Cap
$490.45M
Profitability
Profit margins and return metrics
Profit Margin
-188.09%
Operating Margin
-221.58%
Gross Margin
58.34%
ROE
N/A
ROA
-33.92%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.7%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
3.13
Strong
Quick Ratio
2.92
Excellent
Cash/Share
$0.99
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Gross Margin
64.8%
Op. Margin
-89.6%
Net Margin
-120.6%
Total Assets
$0.2B
Liabilities
$0.2B
Equity
$-0.0B
Debt/Equity
-40.81x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
102%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-04
$-0.14
-18.1% surprise
2025-11-05
$-0.11
-4.2% surprise
2025-08-11
$-0.12
+32.3% surprise
Healthcare Sector Comparison
Comparing AQST against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Profit Margin
-188.09%
This Stock
vs
-16.28%
Sector Avg
+1055.3%
(Superior)
Revenue Growth
9.7%
This Stock
vs
124.04%
Sector Avg
-92.2%
(Slower)
Current Ratio
3.13
This Stock
vs
4.47
Sector Avg
-29.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $490.45M | - | -% | -188.1% | $4.02 | |
|
BWAY
BrainsWay Ltd.
|
NEUTRAL | $490.8M | 68.11 | 11.3% | 14.6% | $12.26 | Compare |
|
KMDA
Kamada Ltd.
|
NEUTRAL | $490.86M | 24.26 | 7.6% | 11.2% | $8.49 | Compare |
|
RGNX
REGENXBIO Inc.
|
BEARISH | $489.85M | - | -107.0% | -113.8% | $9.49 | Compare |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $492.14M | - | -15.3% | -9.0% | $11.94 | Compare |
AQST
Aquestive...
BEARISH
Mkt Cap
$490M
P/E
-
ROE
-%
Price
$4.02
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | TOTH A ERNEST JR | Chief Financial Officer | Sale | 58,254 | $243,094 |
| 2026-03-10 | BARBER DANIEL R | Chief Executive Officer | Sale | 180,677 | $753,965 |
| 2026-03-10 | BOYD PETER E | Officer | Sale | 29,814 | $124,414 |
| 2026-03-10 | BRAENDER LORI J | Officer | Sale | 40,102 | $167,346 |
| 2026-03-10 | JUNG CASSIE | Chief Operating Officer | Sale | 45,791 | $191,086 |
| 2026-03-10 | KORCZYNSKI SHERRY | Officer | Sale | 15,741 | $65,687 |
| 2026-03-10 | CIOFFI MELINA | Officer | Sale | 25,311 | $105,623 |
| 2026-03-09 | TOTH A ERNEST JR | Chief Financial Officer | Stock Award | 95,000 | - |
| 2026-03-09 | BARBER DANIEL R | Chief Executive Officer | Stock Award | 262,000 | - |
| 2026-03-09 | BOYD PETER E | Officer | Stock Award | 80,000 | - |
| 2026-03-09 | BRAENDER LORI J | Officer | Stock Award | 80,000 | - |
| 2026-03-09 | JUNG CASSIE | Chief Operating Officer | Stock Award | 80,000 | - |
| 2026-03-09 | KORCZYNSKI SHERRY | Officer | Stock Award | 75,000 | - |
| 2026-03-09 | CIOFFI MELINA | Officer | Stock Award | 100,000 | - |
| 2026-03-09 | DAVIS MATTHEW W | Officer | Stock Award | 50,000 | - |
TOTH A ERNEST JR
Chief Financial Officer
2026-03-10
58,254 shares
·
$243,094
BARBER DANIEL R
Chief Executive Officer
2026-03-10
180,677 shares
·
$753,965
BOYD PETER E
Officer
2026-03-10
29,814 shares
·
$124,414
BRAENDER LORI J
Officer
2026-03-10
40,102 shares
·
$167,346
JUNG CASSIE
Chief Operating Officer
2026-03-10
45,791 shares
·
$191,086
KORCZYNSKI SHERRY
Officer
2026-03-10
15,741 shares
·
$65,687
CIOFFI MELINA
Officer
2026-03-10
25,311 shares
·
$105,623
TOTH A ERNEST JR
Chief Financial Officer
2026-03-09
95,000 shares
BARBER DANIEL R
Chief Executive Officer
2026-03-09
262,000 shares
BOYD PETER E
Officer
2026-03-09
80,000 shares
BRAENDER LORI J
Officer
2026-03-09
80,000 shares
JUNG CASSIE
Chief Operating Officer
2026-03-09
80,000 shares
KORCZYNSKI SHERRY
Officer
2026-03-09
75,000 shares
CIOFFI MELINA
Officer
2026-03-09
100,000 shares
DAVIS MATTHEW W
Officer
2026-03-09
50,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
Piper Sandler
2025-11-07
Overweight
Overweight
JMP Securities
2025-10-09
Market Outperform
Market Outperform
Past News Coverage
Recent headlines mentioning AQST from our newsroom.
Newest → oldest
No matching news yet.